PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT
This article describes a rare clinical case of prostate cancer with a high baseline PSA level of 1407 hg/ml. In the course of diagnosis, hormonal and surgical treatment there was a successive dynamics of PSA decline: 07.08.2015–1407 ng/ ml, 14.09.2015–43,61ng/ml; 17.11.2015–0,326 ng/ml; 13.02.2016 (...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
QUASAR, LLC
2017-12-01
|
| Series: | Исследования и практика в медицине |
| Subjects: | |
| Online Access: | https://www.rpmj.ru/rpmj/article/view/228 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839573538246230016 |
|---|---|
| author | A. T. Asratov A. S. Kalpinskiy I. A. Taraki Yu. V. Samsonov A. A. Kostin |
| author_facet | A. T. Asratov A. S. Kalpinskiy I. A. Taraki Yu. V. Samsonov A. A. Kostin |
| author_sort | A. T. Asratov |
| collection | DOAJ |
| description | This article describes a rare clinical case of prostate cancer with a high baseline PSA level of 1407 hg/ml. In the course of diagnosis, hormonal and surgical treatment there was a successive dynamics of PSA decline: 07.08.2015–1407 ng/ ml, 14.09.2015–43,61ng/ml; 17.11.2015–0,326 ng/ml; 13.02.2016 (end of hormone therapy) — 0,084 ng/ml. After the operation of radical prostatectomy with enlarged lymphadenectomy, on 20.04.2016 (with prolonged hormone therapy up to 9 monthes) gradual decrease of PSA level continued: 05.05.2016–0,008 ng/ml; 17.06.2016–0,008 ng/ml; 08.09.2016–0,039 ng/ml; 30.11.2016–0,002 ng/ml; 07.09.2017 (total PSA) — 0,008 ng/ml. In parallel, there was a consistent improvement in the clinical picture, up to the MRI data of 19.10.2017, when there were no significant neoplastic changes at the level of the study (in the projection of the prostatic bed). |
| format | Article |
| id | doaj-art-fdfdb2dfbfb3424fbc75b2034d6c1a1c |
| institution | Matheson Library |
| issn | 2410-1893 |
| language | Russian |
| publishDate | 2017-12-01 |
| publisher | QUASAR, LLC |
| record_format | Article |
| series | Исследования и практика в медицине |
| spelling | doaj-art-fdfdb2dfbfb3424fbc75b2034d6c1a1c2025-08-04T14:04:03ZrusQUASAR, LLCИсследования и практика в медицине2410-18932017-12-014413314210.17709/2409-2231-2017-4-4-14178PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENTA. T. Asratov0A. S. Kalpinskiy1I. A. Taraki2Yu. V. Samsonov3A. A. Kostin4P. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian FederationP. Hertsen Moscow Oncology Research Institute – Branch of the National Medical Radiology Research Centre of the Ministry of Health of the Russian FederationThis article describes a rare clinical case of prostate cancer with a high baseline PSA level of 1407 hg/ml. In the course of diagnosis, hormonal and surgical treatment there was a successive dynamics of PSA decline: 07.08.2015–1407 ng/ ml, 14.09.2015–43,61ng/ml; 17.11.2015–0,326 ng/ml; 13.02.2016 (end of hormone therapy) — 0,084 ng/ml. After the operation of radical prostatectomy with enlarged lymphadenectomy, on 20.04.2016 (with prolonged hormone therapy up to 9 monthes) gradual decrease of PSA level continued: 05.05.2016–0,008 ng/ml; 17.06.2016–0,008 ng/ml; 08.09.2016–0,039 ng/ml; 30.11.2016–0,002 ng/ml; 07.09.2017 (total PSA) — 0,008 ng/ml. In parallel, there was a consistent improvement in the clinical picture, up to the MRI data of 19.10.2017, when there were no significant neoplastic changes at the level of the study (in the projection of the prostatic bed).https://www.rpmj.ru/rpmj/article/view/228prostate cancerdynamics of psa levelcombined treatment (hormonal and surgical) |
| spellingShingle | A. T. Asratov A. S. Kalpinskiy I. A. Taraki Yu. V. Samsonov A. A. Kostin PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT Исследования и практика в медицине prostate cancer dynamics of psa level combined treatment (hormonal and surgical) |
| title | PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT |
| title_full | PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT |
| title_fullStr | PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT |
| title_full_unstemmed | PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT |
| title_short | PROSTATE CANCER WITH A HIGH BASELINE PSA LEVEL AFTER COMBINED TREATMENT |
| title_sort | prostate cancer with a high baseline psa level after combined treatment |
| topic | prostate cancer dynamics of psa level combined treatment (hormonal and surgical) |
| url | https://www.rpmj.ru/rpmj/article/view/228 |
| work_keys_str_mv | AT atasratov prostatecancerwithahighbaselinepsalevelaftercombinedtreatment AT askalpinskiy prostatecancerwithahighbaselinepsalevelaftercombinedtreatment AT iataraki prostatecancerwithahighbaselinepsalevelaftercombinedtreatment AT yuvsamsonov prostatecancerwithahighbaselinepsalevelaftercombinedtreatment AT aakostin prostatecancerwithahighbaselinepsalevelaftercombinedtreatment |